



**Niels W C J van de Donk**

## Contact

Niels W C J van de Donk

## Publications (7)

Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Bek sac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof I, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hájek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen E, Vanquickenbergh V, Sitthi-Amorn A, Van de Velde C, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2023; 390:301-313.

Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk N, Ntanasis-Stathopoulos I, Vangsted A, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hájek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos M, Sonneveld P, Ludwig H. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). *Leukemia* 2023; 37:1175-1185.

Sonneveld P, Driessen C, Pour L, Levin M, Bos G, Ypma P, Wu K, van de Velden V, Oliva S, Broijl A, Croockewit A, Boccadoro M, Spencer A, Palumbo G, Offidani M, van de Donk N, Hveding C, Waage A, Minnema M, Troia R, Cornelisse P, Zamagni E, Zander T, Zweegman S, Ludwig H, Aquino S, van der Holt B, Bek sac M, Dimopoulos M, Wester R, Hájek R, Gulbrandsen N, Gregersen H, Morelli A, De Rosa L, Cafro A, Gay F, Dozza L, Pantani L, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. *J Clin Oncol* 2021; 39:3613-3622.

Caers J, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner H, Terpos E, Dimopoulos M, Driessen C, Larocca A, Garderet L, Kortüm K, O'Dwyer M, van de Donk N, Binder M, Dold S, Gay F, Corre J, Beguin Y, Ludwig H, Engelhardt M. An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica* 2018

Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Bek sac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Mateos M, Garderet L, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia* 2018

Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs* 2016; 76:989-990.

Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs* 2016; 76:853-67.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)